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ABSTR...o\CT

Many studies have yielded conflicting results regardi~g the toxic~ty of ~[3,
the peptide which is the principal coml?on~nt <:,f senile. pla~ues III brams
of patients with Alzheimer's disease. Usmg m mtra and zn ~zvo models, ~e
have studied the role of glial cells and extracellular matnx molecules m
mediating the effects of A[3. Glial cells respond to A[3 substrate by
accumulating and depositing chondroitin sulfate proteoglycans (CSPGs)
which are inhibitory to neurite outgrowth. CSPGs are present around the
senile plaque core, an area with both dystrophic neurites an~ a general
decrease in normal neurites. We suggest that CSPG may contnbute to the
pathology by leading to regenerative failure of neurites surrounding
senile plaques.

ASTROCYTIC REACTION TO BRAIN INJURY
Generalized Gliosis
Classical observations by Cajal in the early part of this century described
the changes associated with astrocytes following trauma and diseases of
the CNS. 1 This became known as gliosis and can be defined as the
158
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response of glia to local injury with a characteristic change in
morphology of the responding cells. Such reactive cells assume ramified
.
. 23
processes and develop pronounced hypertrophy and hyperplasIa. '
However, astrocytic response to injury· is somewhat heterogeneous. For
instance, following a penetrating injury to the cerebral cortex, astrocytes
proximal and distal to the lesion demonstrate elevated levels of glial
fibrillary acidic protein and therefore are defined as gliotic. 4 However,
astrocytes closer to the site of injury are phenotypically different to those
that are more distaL Astrocytes surrounding a penetrating injury in the
cortex exhibit hyperplasia as well as hypertrophy, whereas astrocytes away
from the injury site show almost exclusively hypertrophy.5,6 Moreover, it
has been shown that only the astrocytes surrounding the actual injury site
express vimentin, and markers which suggest these cells are undergoing
localized proliferation. 6
It is generally believed that reactive gliosis is the main impediment to
the regenerative efforts of the adult mammalian CNS.7 Such a view is
supported by the experiments of Aguayo and collaborators who
demonstrated. that mature neurons of the CNS retain the ability to
regrow so long as the environment contains elements which provide a
favorable substrate and support the growth of neuronal processes.
However, outgrowth will not occur if the environment presented to the
regenerating axonal process is non-permissive or contains actively
inhibitory elements. In such a way, regenerating CNS neurons can
extend a..xons into the regeneration-promoting areas of peripheral nerve
grafts, but fail to penetrate into the regions where reactive gliosis forms
a glial scar. 8 - 12

Production of ECM Proteins
While it is established that the cells and matrices of glial scars represent
a barrier to axon regeneration, it is still controversial whether it is the
cells themselves or molecules of the extracellular matrix which prevent
process outgrowth. Glial scars 13 consist of a dense meshwork of
hypertrophied astrocytic processes and their associated molecular
matrices 13 - 15 which together present a tortuous path for migrating
growth cones. Although the physical presence of the glial scar creates a
mechanical barrier that limits axon growth, changes in the molecular
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properties of reactive astrocytes associated with a scar could also
contribute to regenerative failure. 16 A decrease in growth promoting
molecules l7,lB or a local upregulation of axon inhibitory molecules by
glia 19 could also diminish regeneration. Many molecules of the
extracellular matrix play important roles during development of the
nervous system and in homeostatic control of the CNS.20,21 Synthesis and
modification of extracellular matrix components by reactive glial cells
may be one of the most important features of the response of the CNS
to injury and disease.
Astrocytes respond to wounds in the central nervous system by the
production of growth factors and various ECM proteins. In addition,
microglia, in regions of neurodegeneration, secrete IL_122 which can
induce TGF~ production and possibly ECM accumulation by astrocytes. 23
Tenascin and laminin are among several glycoproteins increased at
wound sites_ 24 Laminin in particular is one of the most potent neurite
outgrowth promoting molecules that exists. Tenascin can be both growth
promoting or growth inhibiting depending on the presence of associated
molecules. 25 Even though the glial scar produces these and other factors
that could encourage regeneration, nevertheless, it remains an obstacle
to neurite outgrowth. Perhaps, the presence of growth inhibitory
molecules can negate the facilitory effects of these factors.
Many believe that astrocytes respond to mechanical wounds through
the formation of a glial scar in order to re-establish a compromised glial
limitans. Proteoglycans are a m"yor component of the gliallimitans and
it has been demonstrated that proteoglycans are markedly increased in
regions of reactive gliosis due to trauma. 19,26,27 In vitro experiments have
shown that proteoglycans can be potent inhibitors of neurite
outgrowth. 28,29 Thus, their enhanced presence in the glial scar could play
a m,yor role in regenerative failure. This same kind of "walling off'
response by astrocytes also appears to occur around SPs in AD.
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generation from J3PP. Others have suggested a more active role through
the generation of complement attack complexes. 3l Surrounding the AJ3
core are many dystrophic neurites and processes of reactive astrocytes.
Presumably, the cause of astrocyte reactivity is the extensive neuronal
death which occurs throughout the AD brain or their reaction to A[3.
However, a more active role for astrocytes has generally been
32
overlooked and indeed, astrocytes could contribute to the pathology of
the disease by altering the local environment to one that compromises
neuronal viability.

GLIAL REACTION TO AMYLOID
J)-PROTEIN (AJ3)
!.
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Senile plaques consist of a dense core of amyloid f)-protein (A[3), a

40-42 amino acid peptide derived from a larger precursor, J3PP. 30
Microglial cells are found throughout the senile plaque. The specific role
of microglia is unknown although they might be responsible for AJ3

In Vitro Studies
The fmding that AJ3 is normally produced and is found in a soluble
33
.
10rm came as a surpnse to many researchers who viewed AJ3 as an
unwanted, toxic, insoluble byproduct resulting from aberrant proteolysis.
Therefore, the key event in SP formation may not be the generation of
AJ3 per se, but rather factors that promote the accumulation of AJ3. The
cellular responses to A~ are presently being defined and many
conflicting studies have shown that A/3 is toxic or trophic to neurons
depending on the experimental conditions. 34,35 Much of the confusion
of A/3 toxicity may be the result of parameters and factors other than A!3.
AJ3 may not have a direct effect on neurons; instead, it may act indirectly
by affecting other cells or ~ducing the accumulation of other molecules
which are themselves harmful to neurons. Our approach has been to
determine whether glial cells may be involved and whether molecules
secondary to A~ may affect neurons.
In an in vitro mode]36 A!3 is bound to specific areas on a tissue culture
dish and used as a substrate for ceUs. Since AJ3 in the SPs is insoluble
substrate bound A~ may simulate SP-AJ3 better than A!3 added to cultur~
media. Neurons show a preferential adherence to AJ3 and laminin
together over laminin alone, corroborating another report suggesting
that A!3 enhances the growth promoting activity oflaminin. 37 Astrocytes,
on the other hand, change morphology, become highly motile, and
.c
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outgro-wth is correlated with the presence of CSPG as demonstrated in
other systems. 19 ,28,29

In Vivo Studies
Previous studies have examined the role of -A./3 injected into the brains of
35
animals. Some have found neurodegeneration while others have not,
further confounding the controversy of Af3 toxicity. One of the
difficulties in interpreting such data is the variable amount of trauma
which results from minor differences in the penetrating wounds. While
one group found that Af3 injection with proteoglycans yielded fibrillar Af3
which persisted, clear neurodegeneration due to Af3 remains
questionable in view of the compounding effects of trauma and the
formation of a glial scar. 38

Fig. 13.1 A. _!\.strocytes (arrows) grown on A{3 and lamin~n ~ubstrate
accumulate and deposit chondroitin sulfate proteogly~an as mdlcated by
fluorescent antibodies. B. Astrocytes infiltrate a mtrocellulose filter
implanted in a neonatal rat. Here, the filter was coated with ~ prior to
implantation. The astrocytes are immunoreactive for chondrOltm sulfate
proteoglycan.

eventually move off the A~ substrate. Astrocytes in contact with the Af3
substrate accumulate CSPGs and deposit them on the substrate. When
astrocytes are allowed to "precondition" the Af3 subs~ra~e ~~. CSPG, the
substrate becomes inhibitory to neurite growth. This mhlbluon can be
removed by digestion with chondroitinase, an en~~ :v~ch degra~es
chondroitin glycosaminoglycan chains. Therefore, mhlbluon of neurIte

In one model of glial scarring, nitrocellulose filter implants are
inserted into rat cortex. Astrocytes infiltrate the filter, and become
intensely GFAP-positive.1 6 If the injury was made in an adult animal,
these astrocytes accumulated CSPG which inhibits neurite outgrowth.19
In a neonatal animal on the other hand, astrocytes infiltrate the filter,
are GFAP-positive, but do not accumulate CSPG. Further, in the young
animal, neurite outgrowth is possible and there is no glial scar formed.
Since neonatal animals have astrocytic reaction without all of the
characteristics of trauma, we implanted filters which were coated with Af3
to determine the response of these cells. In the presence of A{3, neonatal
astrocytes accumulate CSPG much the same as in the adult animal. While
neurodegeneration was not observed in the young animal, it is
interesting that Af3 causes young astrocytes to react as if they were adult.
CSPGs have been shown to al;cumulate at sites of injury in the adult
central nervous system. 19,27 While a variety of unknown triggers may be
involved in the initiation and maintenance of reactive gliosis and CSPG
accumulation, it appears that Af3 may be one such trigger. In the glial
scar model of neonates, the presence of Af3 may accelerate, or amplify a
normal cellular response. In the adult animal, it has been shown that ~PP
is increased in response to injury.39 It is intriguing to consider the
possibility that f3PP expression could yield Af3 which in turn induces
CSPG at irdury sites. Therefore, one difference between the adult and
young animal may be f3PP expression or processing. Exogenous Af3 in the
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neonate may overcome any difference in J3PP and result in the same
response of the adult, namely CSPG accumulation. This "normal"
response could be increased or more pronounced with aging, thus
explaining the presence of CSPG in adult wounds without exogenous AJ3.

deposition of CSPG may have significant impact on the neuronal
environment in the periphery of senile plaques.

Astrocytes in Several N eurodegenera1ive Diseases
Contain CSPG

PERIPHERY

ENVIRONMENT OF TIIE SEN1LE PLAQUE

As noted earlier, many neurodegenerative diseases display reactive glia as
an aspect of the pathology. Previously, we demonstrated that GFAP
positive astrocytes in cases of Alzheimer's disease also contain CSPG. 36,40
The colocalization is especially noticed in the vicinity of SPs, consistent
with in vitro and in vivo models of CSPG deposition upon an insoluble AJ3
substrate. This observation suggests that AJ3 may be responsible for the
accumulation of CSPG. We wanted to determine whether CSPG
accumulation by reactive astrocytes is specific to Alzheimer's disease, or
if it is common to other conditions of gliosis.
Recently, we demonstrated that reacting astrocytes in several
neurodegenerative diseases contain CSPG.41 While the study focused on
diseases characterized by neuronal inclusions such as Parkinson's disease,
Pick's disease, diffuse Lewy body disease, and progressive supranuclear
palsy, we also examined cases of Huntington's di$ease. None of these
diseases are charactierized by SPs or Aj3 deposition; however, all of them
have CSPG-positive astrocytes. Of particular interest was Huntington's
disease, which has CSPG-containing astrocytes in the basal gangalia but
not in the cortex, suggesting astrocytic CSPG is associated with

neurodegeneration.
",,',lhiIe Af3 may playa key role in CSPG deposition in AD, there may be
other initiators for CSPG accumulation during neurodegeneration. An
important difference between astrocytic CSPG accumulation in AD and
the other neurodegenerative diseases may be deposition. CSPG
immunoreactivity in the other diseases is confmed to the astrocyte itself
and may represent an internal accumulation or accumulation very close
to the surface of the cell. In AD, on the other hand, CSPG is deposited
around the SPs. This corresponds with the in vitro model which indicates
that Aj3 induces CSPG accumulation and deposition. The release and

Rxtracellular Matrix Proteins Associated with Senile
Plaques of Alzheimer's Disease
Increases in specific glycosaminoglycans were initially reported in
extracts made from the brains of Alzheimer's disease patients. 42 Later,
use of cationic dyes such as Alcian blue showed that glycosaminoglycans
are associated with senile plaques (SP). 43 Further experimental
approaches using a basic fibroblast grotvth factor (bFGF) binding assay
indicates heparan sulfate proteoglycans (HSPG) in amyloid deposits,
dystrophic neurites around SPs and extracellular NFTs. 44 ,45
Immunocytochemical experiments indicate that the HSPG in SPs may be
perle can, the basement membrane HSPG. 46 Chondroitin sulfate
proteoglycans show a different distribution than HSPG.40 vVhile HSPG is
found throughout the SP, CSPG is found only in the periphery,
surrounding the Aj3 core. CSPG is also present in intracellular NFTs and
dystrophic neurites as well as reactive astrocytes in the vicinity of senile
plaques. 36 Dermatan sulfate proteoglycan is also present in the SP
periphery.47
In addition to proteoglycans, several other ECM proteins are found in
SPs including fibronectin,48 laminin,49 and collagen type IV.49 These
ECM molecules are neurite outgrmv1:h promoting molecules, and were
hypothesized to promote neurite outgrowth and sprouting in the SP.
Indeed, several studies report increased and aberrant sprouting of
neurites in SPs. These findings support the idea of trophic effects of Aj3
and localization of growth factors in the SP.
ECM-related molecules are also present in SPs including proteases and
protease inhibitors that are involved in the degradation and protection
of ECM molecules. al-antichymotrypsin, al-antitrypsin, anti-thrombin
III, protease nexin I, and other protease inhibitors have been
identified. 50 Proteases including trypsin,51 chymotrypsin, 52 and
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upregulate ECM molecules and protease inhibitors, while downregulating matrix proteases.

Degenerating Neurites
Surrounding the A~ core of the SP are swollen, tortuous neuronal
processes called dystrophic neurites. These neurites contain 1:,56
ubiquitin,57 and show an accumulation of ~PP,58,59 the precursor protein
which generates A~. The exact cause of neuritic dystrophy is unknown;
however, it seems likely that a factor or event in the senile plaque is
responsible, since these lesions are focal. It has long been hypothesized
that A~ itself is the cause of neuritic dystrophy; however, numerous
studies have called this hypothesis into question especially in light of the
AJ3 toxic/trophic debate.
The area surrounding SPs has been shoVl'!l to lack normal neurites. 60
Using neurofilament antibodies, Benes 60 demonstrated that the density
of normal neurites was reduced around SPs. Reduced neurite density
occurred not only in the A~ core as would be expected but also up to twO
plaque core distances away. Surprisingly, some normal neurites curve
around the SP periphery. This suggests that the SP environment, in
addition to causing neuritic dystrophy, may somehow prevent or reduce
normal neurites in this area.

Neuronal Sprouting?

Fig. 13.2 A. bFGF binds to heparanase sensitive sites in senile plaques of
Alzheimer's disease. B. Chondroitin 6-sulfate proteoglycan is found in
the periphery, surrounding the Aj3 core.
metalloprotease 9 53 have also been localized to SP. One recent
hypothesis suggests that a proteolytic imbalance occurs in the area of a
SP.54 The accumulation of ECM proteins in SPs might be the result of
decreased matrix turnover. Indeed, the presence of TGF~55 in SPs could

Another hypothesis for the cause of neuritic dystrophy is aberrant
sprouting of neurons. 61 Many growth factors and growth promoting
molecules have been found in SPs including bFGF,62 laminin and
collagen. Growth associated proteins such as GAP43 63 and NTP64 have
been identified in neurites of SPs. \-Vhile it has been suggested that
excessive or abnormal sprouting of neurites due to increased trophism
may cause neuritic dystrophy, the relation of these molecules to
regeneration has not been overlooked. 55 Indeed, GAP43 and the other
growth promoting/associated molecules are all characteristic of wound
or regeneration related molecules.
This suggests a different view of the neurites and ECM proteins in SPs.
Instead of a growth promoting, trophic environment for excessive
neurite outgrowth, the SP may prevent the restoration of synapses by
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inhibiting neuritic infiltration into the area. Such an idea is supported by
the bulbous, dystrophic neurites found in A~ deposits of AD brain which
differ from degenerating neurites found in other neurological
conditions 66 and are not characterized by large, focal, extracellular
deposits of wound related molecules_

Why is there a Halo?
Further evidence suggests that the periphery around the SP, rather than
the core itself, has the greatest impact on neurons. When retinal
ganglion cells are grown on cryostat sections of AD brain67 they attach
and put forth processes. No difference in the density of neurons which
attach to SP cores and those which attach to areas lacking SPs is noted.
However, the number which adhere to the periphery of SPs was
substantially decreased. In addition, grow-th in this peri-plaque region is
inhibited and neurons are more likely to extend a process away rather
than toward SPs. Some neurons were obseIVed which initially grow
toward a SP but then CUIVe and turn away. These results are consistent
with the observations of a lack of normal neurites in the periphery of SPs.
As neurons die throughout the brain in AD, there may be an attempt
to recover some of the lost synapses through collateral sprouting.
Astrocytic deposition of CSPG may impact this process by inhibiting
neurite outgrowth, thus preventing the sprouts from reaching their
potential targets. Therefore, while the number of synapses, neurons, and
neurite density decreases throughout the brain in AD, attempts at
recovery are possible except in the area of the periphery of the SP where
CSPG prevents neuritic outgrowth as well as synaptic restoration. Synapse
loss is accentuated in SPs, but not in diffuse SPs where there is no
distinction from the rest of the neuropil. 68 Interestingly, diffuse SPs do
not have CSPG accumulation. Therefore, the presence of CSPG is
correlated with increased synaptic pathology in the AD brain.
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Role of Inflammation and
Complement Activation in
Alzheimer's Disease
R. Veerhuis, 5.-5. Zhan
and
P. Eikelenboom

ABSTRACT

A variety of inflammatOry proteins has been identified, particularly in the
vicinity of /3-amyloid plaques, in the brain of patients INith Alzheimer's
disease. Current findings indicate that these molecules are involved in a
num?er of key steps in the parbological cascade. Activation products of
ClasSICal complement pathway Clq, C4 and C3, but not the alternative
pathway factor properdin, have been demonstrated in diffuse and
classical plaques. In addition, complement receptors (CR3 and CR4)
bearing cells are found within classical plaques. There are contradictory
findings about the question whether or not the late complement proteins
that can form the membrane attack complex, are present in Alzheimer's
disease brains.
In this chapter we review the findings indicating that complement
activation in amyloid plaques does not proceed further than C3. The idea
is discussed that in Alzheimer's disease, complement does not function as
an inflammatory mediator through membrane attack complex formation,
but through the action of early complement activation products.
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